Anavex Life Sciences Strengthens Management Team and Board of Directors
March 05 2018 - 7:00AM
Company Appoints Stephan Toutain as Senior Vice
President of Operations and Claus van der Velden to Board of
Directors
Anavex Life Sciences Corp. (“Anavex” or the “Company”)
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company
developing differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, Rett syndrome and other central nervous system
(CNS) diseases, announced today the addition of Stephan Toutain,
MS, MBA as Senior Vice President Operations to its management team
and the appointment of Claus van der Velden, PhD to the Board of
Directors.
“We are delighted to welcome Stephan and Claus
to Anavex. These appointments are a commitment to building our team
in order to advance the development of ANAVEX2-73 in devastating
neurological diseases like Rett syndrome, Alzheimer’s disease and
Parkinson’s disease. Stephan is a seasoned business leader and an
experienced operations and marketing executive who will lead the
acceleration of our product development strategy, while Claus’
expertise will provide strategic guidance, compliance and
accounting oversight on the Board of Directors,” said Christopher
U. Missling, PhD, President and Chief Executive Officer of
Anavex.
Stephan Toutain, MS, MBA, SVP Operations
Stephan Toutain brings more than 25 years of
drug development, general management, operations, commercial
development, market access, and sales and marketing leadership with
particular expertise in neurology and orphan drug markets globally.
Before joining Anavex, he held the role of CCO at Interleukin
Genetics. He also worked with Alnylam Pharmaceuticals to build its
early access program. Previously, he led Global Commercial
Development for Sarepta Therapeutics and served as General Manager
for Alexion Pharmaceuticals in Europe. Mr. Toutain has also held
various U.S. commercial, marketing and product management positions
with Alexion Pharmaceuticals, Celgene Corporation, and Johnson
& Johnson. He received a Master of Business Administration from
the University of North Carolina, and a Master of Engineering in
Biotechnology from the University of Nancy II in France.
Claus van der Velden, PhD, Board of
Directors
Claus van der Velden, PhD, brings significant
expertise in accounting and is currently corporate head of
Management Accounting, Internal Audit and Risk Management
at Stroeer SE & Co KGaA, a publicly listed $3bn media
company. Previously, Dr. van der Velden served as Director,
Corporate Business Controlling for the Nutrition & Health
business unit at Cognis, a worldwide supplier of global nutritional
ingredients and specialty chemicals with about $3bn sales. In this
position, he was also a compliance representative and a member of
the global leadership team. After the acquisition of Cognis by
BASF, he was responsible for the management accounting processes of
the $2bn BASF Nutrition & Health division, developing and
producing mostly natural-source ingredients for the food and
healthcare industries. Dr. van der Velden started his career as a
strategy consultant at an international marketing and strategy
consultancy firm. He studied in Kiel and Stockholm and received a
degree in economics from the University of Kiel and later obtained
his doctorate from the WHU-Otto Beisheim School of Management.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’ lead drug candidate,
ANAVEX®2-73, recently completed a successful a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research has awarded Anavex a research grant to develop ANAVEX®2-73
for the treatment of Parkinson’s disease. The grant fully funds a
preclinical study, which could justify moving ANAVEX®2-73 into a
Parkinson’s disease clinical trial. ANAVEX®3-71, targeting sigma-1
and M1 muscarinic receptors, is a promising preclinical drug
candidate demonstrating disease modifications against the major
Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available at www.anavex.com.
You can also connect with the company on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Clayton
RobertsonThe Trout Group(646) 378-2900Email:
crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024